Kardiolytics gets a US patent for AI-aided diagnostics

Kardiolytics, a company within the Medicalgorithmics group, has obtained a patent for an autonomous method of modeling blood vessels using medical imaging data, which is expected to be used in diagnosing vascular diseases. This is the second patent awarded to Kardiolytics this year in the VCAST technology by the US Patent Office. The VCAST system is a non-invasive technology for diagnosing coronary arteries, using artificial intelligence and tomography.

Kardiolytics estimates that the global CT-FFR market will reach a value of $1.3 billion by 2026, driven by an increasing number of people suffering from coronary artery disease, an aging population, and advancements in CT technology making it more accessible to patients.

Source: strefainwestorow.pl